Luis Gerardo García Herreros

Luis Gerardo García Herreros

Auto-generated profile, based on publicly available information

Luis Gerardo García Herreros

Fundación Santa Fe de Bogota, Bogota, Colombia

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2024 in Case Reports in Surgery
Verified
Journal Article
Open access
DMDiego Salcedo Miranda
Diego Salcedo Miranda
JOJorge Roberto Galvis O.
Jorge Roberto Galvis O.
LGLuis Gerardo García-Herreros
Luis Gerardo García-Herreros
DCDavid Torres Cortes
David Torres Cortes
OROscar Rivero Rapalino
Oscar Rivero Rapalino
Paraganglioma of the middle mediastinum has a prevalence of 1%–2% of paragangliomas and less than 1% of mediastinal masses. It is generally asymptomatic and can easily be confused with other pathologies. The following is the case of a 50‐year‐old patient who, as an incidental finding, documented an injury between the aorta and the pulmonary artery, hypervascularized, which was embolized prior to surgery, which facilitated the complete resection of the lesion by sternotomy. With favorable evolution of the patient and discharge on the fourth postoperative day. A thorough review of the literature on the diagnostic and treatment approach to this pathology has been also carried out.

29 June 2023 in Revista Colombiana de Cancerología
Verified
Journal Article
Open access
PDF file
FSFernando Alvarado Sarzosa
Fernando Alvarado Sarzosa
SJStella Isabel Martínez Jaramillo
Stella Isabel Martínez Jaramillo
LHLuis Gerardo García-Herreros Hellal
Luis Gerardo García-Herreros Hellal
RJRafael José Beltrán Jiménez
Rafael José Beltrán Jiménez
JRJuan David Zuluaga Restrepo
Juan David Zuluaga Restrepo
CFCarlos Andrés Carvajal Fierro
Carlos Andrés Carvajal Fierro
Introducción: En Colombia, la información de la supervivencia de los pacientes con cáncer de pulmón tratados en estadio temprano es limitada. El objetivo de este estudio fue analizar los desenlaces clínicos y los factores asociados al pronóstico de los pacientes con cáncer de pulmón de célula no pequeña (CPCNP) con manejo quirúrgico en tres instituciones de Bogotá. Métodos: Estudio observacional, analítico, retrospectivo, multicéntrico. Resultados: Se incluyeron 101 pacientes con una mediana de edad de 69 años (IQR 63-75), de ellos, 56 (55,4 %) mujeres. Ocho (7,9 %) pacientes tenían un estadio patológico 0; 83 (82,2 %), estadio I y 10 (9,9 %), estadio II. La supervivencia libre de enfermedad (SLE) a tres años de los pacientes con estadios 0, I y II fue de 100 %, 97 % y 58 %, respectivamente. La supervivencia global (SG) a tres años de todos los pacientes incluidos fue del 94 %. La SG con y sin recaída fue de 78 % y 96 %. Se encontraron asociaciones estadísticamente significativas entre recaída y estadio II (P< 0,001), recaída y T3 (P=0,048), recaída y N1 (P<0,001) y recaída y compromiso de la pleura visceral (P=0,002). La única asociación encontrada con el fallecimiento de los pacientes fue la recaída (P=0,002). Conclusiones: El estadio patológico y algunas características especiales del TNM, ser T3, la presencia de N1 y la invasión de la pleura visceral fueron factores determinantes en la SLE. Por otro lado, el único factor que se asoció con peor SG fue la recaída.

23 September 2025 in Respirar
Verified
Journal Article
Open access
PDF file
ITIvan Triana
Ivan Triana
IHIsabel Hernández-Linares
Isabel Hernández-Linares
AAAngela Aguirre
Angela Aguirre
JRJairo Hildebrando Roa
Jairo Hildebrando Roa
OGOlga Milena García
Olga Milena García
LHLuis Gerardo García Herreros
Luis Gerardo García Herreros
Background: Lung cancer is frequently diagnosed in advanced stages and is currently the leading cause of cancer-related mortality worldwide. A multidisciplinary approach is crucial to optimize diagnosis, treatment and improve patient survival. Methods: A retrospective cohort analytical study over two time periods, including patients over 18 years old with early-stage lung adenocarcinoma treated at a high-complexity oncology center in Colombia. The exposure group (2021-2023) received multidisciplinary care, while the non-exposure group (2018-2020) was managed conventionally by individual specialists. The study aimed to compare clinical outcomes and treatment times between both groups. Statistical analysis was based on the distribution of variables. Results: A total of 34 patients were included. The multidisciplinary approach enabled earlier diagnosis of lung adenocarcinoma, increasing early-stage identification from 30% to 61% between 2018 and 2022. Additionally, the multidisciplinary group had a higher proportion of asymptomatic cases (54% vs. 32%) and a lower relapse rate (7% vs. 52%) compared to conventional management. Treatment initiation times were significantly reduced from 3.2 to 2.2 months (p < 0.05), and the time from pathology to treatment decreased to 30 days in the multidisciplinary group versus 85 days in the conventional group. Conclusions: The multidisciplinary approach reduced waiting times for the initiation of cancer treatment, increased treatment adherence and improved clinical outcomes.